Page 120 - 80 guidelines for the treatment of malaria_opt

nd
Guidelines for the treatment of malaria – 2 edition

51. Mihaly GW et al. Pharmacokinetics of primaquine in man: identification of the carboxylic
acid derivative as a major plasma metabolite. British Journal of Clinical Pharmacology, 1984,
17:441–446.
52. Chan TK, Todd D, Tso SC. Drug-induced haemolysis in glucose-6-phosphate dehydrogenase
deficiency. British Medical Journal, 1976, 2:1227–1229.
53. McGready R et al. The pharmacokinetics of atovaquone and proguanil in pregnant
women with acute falciparum malaria. European Journal of Clinical Pharmacology, 2003,
59:545–552.
54. Sabchareon A et al. Efficacy and pharmacokinetics of atovaquone and proguanil in children
with multidrug-resistant Plasmodium falciparum malaria. Transactions of the Royal Society
of Tropical Medicine and Hygiene, 1998, 92:201–206.
55. Helsby NA et al. The pharmacokinetics and activation of proguanil in man: consequences of
variability in drug metabolism. British Journal of Clinical Pharmacology, 1990, 30:593–598.
56. Kaneko A et al. Proguanil disposition and toxicity in malaria patients from Vanuatu with
high frequencies of CYP2C19 mutations. Pharmacogenetics, 1999, 9:317–326.
57. Wattanagoon Y et al. Single dose pharmacokinetics of proguanil and its metabolites in
healthy subjects. British Journal of Clinical Pharmacology, 1987, 24:775–780.
58. Hussein Z et al. Population pharmacokinetics of proguanil in patients with acute P.
falciparum malaria after combined therapy with atovaquone. British Journal of Clinical
Pharmacology, 1996, 42:589–597.
59. Wangboonskul J et al. Single dose pharmacokinetics of proguanil and its metabolites in
pregnancy. European Journal of Clinical Pharmacology, 1993, 44:247–251.
60. McGready R et al. Pregnancy and use of oral contraceptives reduces the biotransformation
of proguanil to cycloguanil. European Journal of Clinical Pharmacology, 2003, 59:553–557.
61. Veenendaal JR, Edstein MD, Rieckmann KH. Pharmacokinetics of chlorproguanil in man
after a single oral dose of Lapudrine. Chemotherapy, 1988, 34:275–283.
62. White NJ et al. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated
falciparum malaria. American Journal of Medicine, 1982, 73:564–572.
63. van Hensbroek MB et al. Quinine pharmacokinetics in young children with severe malaria.
American Journal of Tropical Medicine and Hygiene, 1996, 54:237–242.
64. Supanaranond W et al. Disposition of oral quinine in acute falciparum malaria. European
Journal of Clinical Pharmacology, 1991, 40:49–52.
65. Waller D et al. The pharmacokinetic properties of intramuscular quinine in Gambian
children with severe falciparum malaria. Transactions of the Royal Society of Tropical
Medicine and Hygiene, 1990. 84:488–491.
66. White NJ. Optimal regimens of parenteral quinine. Transactions of the Royal Society of
Tropical Medicine and Hygiene, 1995, 89:462–464.
67. Silamut K et al. Binding of quinine to plasma proteins in falciparum malaria. American
Journal of Tropical Medicine and Hygiene, 1985, 34:681–686.
68. Silamut K et al. Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of
quinine in falciparum malaria. British Journal of Clinical Pharmacology, 1991, 32:311–315.

106